Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Leerink Partners raised its target for Bristol-Myers Squibb from $55 to $73, citing optimism for the company's products Cobenfy (KarXT) and milvexian, a novel blood thinner. Similarly, BMO Capital ...
Leerink Partners raised its target for Bristol-Myers Squibb from $55 to $73, citing optimism for the company's products Cobenfy (KarXT) and milvexian, a novel blood thinner. Similarly, BMO Capital ...
AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
Cobenfy (KarXT), which demonstrated superior efficacy. These factors collectively influenced David Risinger to maintain a Hold rating for AbbVie, reflecting a cautious stance while the company ...
Bank stocks largely boosted the Dow, as investors hope the sector could see weaker regulation in a second Trump ...
BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback